Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Giulia Benevolo et al.|Journal of Clinical Oncology|2014Cited by 210
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Antonio Palumbo, Valeria Magarotto et al.|Blood|2013Cited by 82
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched studyFortunato Morabito, Massimo Offidani, Sara Galimberti et al.|American Journal of Hematology|2013Cited by 26
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) PatientsSara Bringhen, Mario Boccadoro, Valeria Magarotto et al.|Blood|2016Cited by 7